Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs State Street SPDR S&P Biotech ETF — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.42, while State Street SPDR S&P Biotech ETF trades at $152.24. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, JPMorgan Nasdaq Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| JEPQ | XBI | |
|---|---|---|
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $61.46 | $164.28 |
52-Week Low | $53.77 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $58.59 with minimal daily movement (+0.14%). The ETF maintains a bearish technical outlook with selling pressure outweighing buying signals 15-3. Recent dividend distributions of $0.64, $0.56, and $0.59 demonstrate consistent income generation, though technical indicators show RSI at oversold levels near 27. The fund's covered-call strategy provides income but limits upside during strong Nasdaq rallies.
JEPQ offers investors Nasdaq-100 exposure with monthly income via covered calls, yielding approximately 10.7%. However, the strategy caps upside potential during tech rallies, with analysis showing underperformance versus QQQ. Current bearish technicals and competitive pressure from newer ETFs like GPIQ present near-term challenges for price appreciation despite the attractive yield.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
